Botanix Pharmaceuticals (ASX:BOT) has welcomed news that its partner Dongwha Pharm has secured regulatory approval for ECCLOCK gel, 5% (sofpironium bromide) in South Korea, paving the way for the product’s commercial launch in the first quarter of 2026.
Botanix announces regulatory approval of ECCLOCK in South Korea
September 7, 2025 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Week in Review' Podcast - 15 May
May 15, 2026 - - Podcast -
New Zealand still falling behind on access to modern medicines
May 15, 2026 - - Latest News -
AusBiotech welcomes Budget's creation of new National Resilience and Science Council
May 15, 2026 - - Latest News -
Minister fired the starting gun in March, he flung the door open in Budget week
May 14, 2026 - - Latest News -
There are a number of reasons to criticise the minister on the PBS, but he is right to be annoyed about this
May 14, 2026 - - Latest News -
Long-term study finds continuing Mounjaro helps maintain weight loss
May 14, 2026 - - Latest News -
Frustrated minister encourages an early negotiation of new agreements
May 14, 2026 - - Latest News
